Virtual Library

Start Your Search

Samina Park



Author of

  • +

    MA06 - Challenges in the Treatment of Early Stage NSCLC (ID 124)

    • Event: WCLC 2019
    • Type: Mini Oral Session
    • Track: Treatment of Early Stage/Localized Disease
    • Presentations: 1
    • Now Available
    • +

      MA06.12 - Discussant - MA06.09, MA06.10, MA06.11 (Now Available) (ID 3738)

      13:30 - 15:00  |  Presenting Author(s): Samina Park

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.17 - Treatment of Early Stage/Localized Disease (ID 189)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Treatment of Early Stage/Localized Disease
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.17-04 - Role of Lymphadenectomy in Thoracoscopic Lobectomy for Non-Small Cell Lung Cancer (ID 403)

      10:15 - 18:15  |  Presenting Author(s): Samina Park

      • Abstract
      • Slides

      Background

      The adequacy of lymphadenctomy in video-assisted thoracoscopic surgery (VATS) for the patients with non-small cell lung cancer (NSCLC) has been questioned. This study aims to identify the role of lymphadenectomy during VATS lobectomy for NSCLC.

      Method

      To include different level of lymphadenectomy proficiency and heterogeneous lymphadenectomy policy, we included all consecutive surgical cases from April 2005 to June 2013, irrespective of surgeon’s experience, lymph node sampling or dissection, and solid or subsolid nodule. Patients who underwent VATS lobectomy and who were followed up for more than 5 years were included in this study. The relationship between long-term survival and the number of removed lymph nodes was analyzed.

      Result

      During the study period, a total of 2,502 patients underwent curative surgical resection of NSCLC and VATS lobectomy was performed in 1,055 patients (42.2%). The median length of postoperative hospital stay was 5 days and 30-day and 90-day all-cause mortality rates were 0.3% and 0.9%, respectively. Pathological stage I, II, III and IV were 79.0%, 10.6%, 8.7%, and 1.7% and the median number of removed lymph nodes was 24. The 5-year overall and recurrence-free survival rates were 83.9% and 78.5 %, respectively. Recurrences were developed in 233 patients (22.1%) and the most common pattern was distant metastasis (n=153, 14.5%). The number of removed lymph nodes, year of operation, age, tumor size, pathologic stage, histology, and radiologic features were the significant prognostic factor for recurrence-free survival in multivariate analysis. More than 10 lymph node removal was associated with improved recurrence-free survival and the effect lasted until 40. However, the number of removed lymph nodes were not a significant risk factor for overall survival (table).

      Conclusion

      The number of removed lymph nodes was closely related with recurrence-free survival after VATS lobectomy. Proper lymphadenectomy should be performed in VATS lobectomy like as open lobectomy.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.